The stock has a 36-month beta value of 1.05. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ZLAB is 98.42M, and at present, short sellers hold a 2.84% of that float. On June 28, 2024, the average trading volume of ZLAB was 611.36K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ZLAB) stock’s latest price update
The stock of Zai Lab Limited ADR (NASDAQ: ZLAB) has decreased by -1.20 when compared to last closing price of 17.52. Despite this, the company has experienced a -6.79% fall in its stock price over the last five trading sessions. businesswire.com reported 2024-06-11 that SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume resp.
ZLAB’s Market Performance
ZLAB’s stock has fallen by -6.79% in the past week, with a monthly drop of -3.62% and a quarterly rise of 8.05%. The volatility ratio for the week is 4.20% while the volatility levels for the last 30 days are 4.68% for Zai Lab Limited ADR The simple moving average for the past 20 days is -8.15% for ZLAB’s stock, with a -21.13% simple moving average for the past 200 days.
Analysts’ Opinion of ZLAB
Many brokerage firms have already submitted their reports for ZLAB stocks, with Morgan Stanley repeating the rating for ZLAB by listing it as a “Overweight.” The predicted price for ZLAB in the upcoming period, according to Morgan Stanley is $47.50 based on the research report published on December 14, 2023 of the previous year 2023.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see ZLAB reach a price target of $70. The rating they have provided for ZLAB stocks is “Overweight” according to the report published on August 10th, 2023.
Macquarie gave a rating of “Outperform” to ZLAB, setting the target price at $64 in the report published on January 21st of the previous year.
ZLAB Trading at -4.46% from the 50-Day Moving Average
After a stumble in the market that brought ZLAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.90% of loss for the given period.
Volatility was left at 4.68%, however, over the last 30 days, the volatility rate increased by 4.20%, as shares sank -4.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.38% upper at present.
During the last 5 trading sessions, ZLAB fell by -6.62%, which changed the moving average for the period of 200-days by -34.66% in comparison to the 20-day moving average, which settled at $18.80. In addition, Zai Lab Limited ADR saw -36.66% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZLAB starting from Du Ying, who sale 23,939 shares at the price of $17.90 back on Jun 26 ’24. After this action, Du Ying now owns 1,142,833 shares of Zai Lab Limited ADR, valued at $428,532 using the latest closing price.
Reinhart Harald sale 7,431 shares at $17.90 during a trade that took place back on Jun 26 ’24, which means that Reinhart Harald is holding 62,619 shares at $133,022 based on the most recent closing price.
Stock Fundamentals for ZLAB
Current profitability levels for the company are sitting at:
- -1.26 for the present operating margin
- 0.63 for the gross margin
The net margin for Zai Lab Limited ADR stands at -1.16. The total capital return value is set at -0.46. Equity return is now at value -38.44, with -31.41 for asset returns.
Based on Zai Lab Limited ADR (ZLAB), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -3.46. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -17.93.
Currently, EBITDA for the company is -358.84 million with net debt to EBITDA at 1.83. When we switch over and look at the enterprise to sales, we see a ratio of 3.82. The receivables turnover for the company is 3.84for trailing twelve months and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.63.
Conclusion
To sum up, Zai Lab Limited ADR (ZLAB) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
